EGAPP recommendations on three genetic tests

view article

Published at: www.phgfoundation.org

US Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommendations do not support rapid increase in diagnostic testing based on available evidence and methodologies

January 30, 2009

Analysis by: GLG Expert Contributor

The EGAPP working group has produced well researched and documented reommendations for the use of genetic testing in metastatic colorectal cancer, Lynch syndrome, and Breast Cancer.      The absence of clearcut positive recommendations for defined testing strategies and methodologies would seem to suggest significant risk for meeting growth targets for products already in this space.  In a time of potential for cost containment pressure, the absence of strong affirmative recommendations would provide support for those physicians not wanting to use, or insurers not willing to reimburse, some of the affected testing methods.     While these recommendations would appear to provide openings for other entrants on the market, te evaluation indicates the type of scrutiny that new tests will face as they are developed.

Ken PowellPresidentGenesis Business Development, LLC

Genetic Test Recommendations from EGAPP

January 29, 2009

The US Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (EWG) released its genetic testing recommendations for metastatic colorectal cancer, Lynch syndrome and breast cancer.  These recommendations join others from various public and private groups calling for increased scrutiny and regulation of genetic tests.